For patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, adjuvant trastuzumab ...

Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...

Patients with HER-2 positive early breast cancer with residual invasive disease after neoadjuvant therapy were randomly ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in ...

Enliven's initial phase 1 data for ELVN-001 in CML shows promising tolerability and activity in heavily pretreated patients. But read why ELVN stock is a Sell.

Overall, national sales volume of trastuzumab emtansine showed average growth, reaching $1 million in September 2021 and fluctuated around $0.9 million. Study results suggest biosimilars can invoke a ...

Among these, Tisotumab vedotin had the most positive signals at the preferred terms (PTs) level, followed by trastuzumab emtansine and enfortumab vedotin. In contrast, gemtuzumab ozogamicin ...